ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 839

A Paradigm Change for Treatment Strategies for Fibromyalgia Syndrome Reflected By Recommendations of Recent Evidence-Based Interdisciplinary Guidelines Developed Independently in Three Countries

Jacob N. Ablin1, Dan Buskila2, Howard Amital3, Mary-Ann Fitzcharles4, Yoram Shir5, Peter Henningsen6 and Winfried Häuser7, 1Rheumatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 2Ben-Gurion University, Beer-Sheva, Israel, 3Department of Medicine B, Center for Autoimmune Diseases, Sheba Medical Center, Tel-hashomer, Israel, 4Rheumatology & Alan Edwards Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada, 5Alan Edwards Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada, 6Department Internal Medicine I, Klinikum Saarbrücken, Saarbrücken, Germany, 7Klinikum Saarbrücken, Saarbrücken, Germany

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: fibromyalgia, guidelines and treatment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Fibromyalgia, Soft Tissue Disorders and Pain: Diagnosis and Disease Epidemiology

Session Type: Abstract Submissions (ACR)

Background/Purpose: Although the ideal treatment for fibromyalgia (FM) remains elusive, the medical community requires direction in the care of these patients.  The literature however abounds with copious reports of various treatments that drive health-care costs, but provide ever increasing confusion for patients and physicians. We have compared treatment recommendations for FM provided by recent evidence-based guidelines.

Methods: Systematic searches from January 2008 to February 2013 of the US-American National Guideline Clearing House, the Scottish Intercollegiate Guidelines Network, Guidelines International Network and Medline for evidence-based interdisciplinary guidelines on the management of FM were conducted. Inclusion criteria required that the guideline was commissioned by a scientific organisation, the guideline group was interdisciplinary, the systematic search strategy was outlined, criteria and process for classification of evidence and recommendations were stated.

Results: Three evidence-based interdisciplinary guidelines for the treatment of FM in Canada, Germany and Israel fulfilled inclusion criteria.  All three guidelines emphasized a patient-tailored approach according to key symptoms. Non-pharmacologic strategies were the major positive first choice recommendation for all with emphasis on aerobic exercise, cognitive behavioural therapy and multicomponent therapy (exercise and psychological). Acupuncture, hypnosis/guided imagery and Tai Chi were recommended by the German and Israeli guideline, whereas the Canadian guidelines indicated only short term benefits for acupuncture, and categorized   hypnosis/guided imagery and Tai Chi as psychological and exercise interventions respectively with some evidence for effect, but none were specifically recommended. Pharmacologic treatments were less enthusiastically recommended by all three groups. With the qualifier that drugs provide only modest effect, the Canadian and Israeli guidelines gave strong recommendation for the anticonvulsants (gabapentin and pregabalin) and serotonin noradrenaline reuptake inhibitors, whereas these drug categories received only weak recommendation by the German guideline. All groups cautioned about the side effects of drugs manifesting as symptoms of FM.  Use of strong opioids was discouraged by all, with the Israeli and German guideline providing specific negative recommendation for many other drug categories including non-steroidal agents, systemic steroids, benzodiazepines, thyroid hormone replacement, amongst others. Although not providing specific negative treatment recommendations, the Canadian guidelines cited lack of evidence to support many treatments which would therefore constitute “off-label” use.

Conclusion: Recent evidence-based interdisciplinary guidelines concur on the importance of treatments tailored to the individual patient and further emphasize the necessity of self-management strategies which include exercise and psychological techniques.  Contrary to popular perception, drug treatments were recommended with reservation regarding both efficacy and side effect profile.


Disclosure:

J. N. Ablin,

Pfizer Inc,

8;

D. Buskila,
None;

H. Amital,

Pfizer Inc,

2;

M. A. Fitzcharles,

Purdue Pharma L.P.,

5,

Eli Lilly and Company,

5,

Pfizer Inc,

5,

Valeant,

5;

Y. Shir,

Purdue Pharma L.P.,

8,

Paladin Labs,

8,

Paladin Labs,

5;

P. Henningsen,

Novartis Pharmaceutical Corporation,

5;

W. Häuser,

Pfizer Inc,

5,

Daiichi Pharmaceutical Corporation,

5,

Abbott Laboratories,

5.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-paradigm-change-for-treatment-strategies-for-fibromyalgia-syndrome-reflected-by-recommendations-of-recent-evidence-based-interdisciplinary-guidelines-developed-independently-in-three-countries/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology